

BIOforum Europe / 27.11.2008

Step Change in Life Sciences

Within the European SIMDAT project at GlaxoSmithKline (GSK) a substantial progress in pharmaceutical analysis has been achieved. It enables pharmaceutical companies to virtualise and globalise their Research and Development (R&D) chain, lowering costs as

well as considerably improving knowledge exchange between industrial and academic partners. In the opinion of Prof. Ulrich Trottenberg, director of Fraunhofer Institute for Algorithms and Scientific Computing SCAI, the SIMDAT project co-ordinator, one of the most important R&D strategies to achieve

a significant gain of efficiency is to tap into external knowledge and expertise through a network of external alliances, sharing the risk, reward and control. Given the large investments in drug research, virtualisation provides a great savings potential.

www.scai.fraunhofer.de